Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GDM increases asthma risks during pregnancy, urging early screening and improved care for better maternal outcomes.

Asthma represents a substantial health burden in childhood globally, with minoritised populations being disproportionately impacted.1 Recent literature has increasingly linked social determinants of ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...